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Abstract
Background: Chloroquine (CQ) or sulfadoxine-pyrimethamine (SP) monotherapy for Plasmodium
falciparum often leads to therapeutic failure in Indonesia. Combining CQ with other drugs, like SP,
may provide an affordable, available and effective option where artemisinin-combined therapies
(ACT) are not licensed or are unavailable.
Methods:  This study compared CQ (n = 29 subjects) versus CQ + SP (with or without
primaquine; n = 88) for clinical and parasitological cure of uncomplicated falciparum malaria in the
Menoreh Hills region of southern Central Java, Indonesia. Gametocyte clearance rates were
measured with (n = 56 subjects) and without (n = 61) a single 45 mg dose of primaquine (PQ).
Results: After 28 days, 58% of subjects receiving CQ had cleared parasitaemia and remained
aparasitaemic, compared to 94% receiving CQ combined with SP (p < 0.001). Msp-2 genotyping
permitted reinfection-adjusted cure rates for CQ and CQ combined with SP, 70% and 99%,
respectively (p = 0.0006).
Conclusion: Primaquine exerted no apparent affect on cure of asexual stage parasitaemia, but
clearly accelerated clearance of gametocytes. CQ combined with SP was safe and well-tolerated
with superior efficacy over CQ for P. falciparum parasitaemia in this study.
Background
Chloroquine (CQ) was the mainstay of antimalarial ther-
apy from 1946 until the past decade when parasite resist-
ance rendered it clinically ineffective in most areas of the
world. Adult CQ therapy costs less than $0.20, is widely
available almost anywhere in endemic areas, and has a
generally good safety and tolerability profile. Resource-
strapped health agencies in endemic areas struggle with
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the decision to abandon this drug. Alternative drugs, such
as artemisinin combination therapies (ACT), carry signif-
icant limitations linked to cost, ease of compliance and
safety in vulnerable populations like infants and pregnant
women. Combining antimalarials of differing mecha-
nisms of action may diminish risk of onset of parasite
resistance[1], but there are many other determinants of
effectiveness and the more effective the therapeutic
options available, the more likely treatment will result in
a favorable clinical outcome.
CQ combined with sulfadoxine-pyrimethamine (SP) has
been proven safe and effective in clinical trials (Table 1)
and has been adopted as the primary therapy for uncom-
plicated falciparum malaria in several countries. Despite
the slight increase in cost of using two medications (from
approximately $0.10 to $0.20), CQ combined with SP
was proven cost-effective [2]. In some nations, this com-
bination is first-line therapy (e.g. Papua New Guinea,
Vanuatu, Philippines, Uganda, and Ethiopia). Combining
CQ and SP offers compelling advantages in places like
Indonesia, principally because both drugs are licensed,
widely available, familiar to providers and patients, inex-
pensive, relatively safe, well tolerated, and easily adminis-
tered. Furthermore, CQ + SP combined therapy was
recently adopted by Papua New Guinea[3] where the level
of drug resistance is on par with the most drug resistant
areas of Indonesia. Adoption of CQ + SP combined ther-
apy for Plasmodium falciparum would require little more
than a modification of malaria therapeutic policy and
practice. In contrast, most other combined therapy
options would require licensing, acquisition, socializa-
tion, and carry unfamiliar and perhaps more severe risks
linked to safety or compliance. This is an especially salient
problem for pregnant women and young children, for
whom almost no safety data exists.
Clinical data for CQ combined with SP is still lacking in
many countries, including Indonesia, where CQ and SP-
resistant P. falciparum is prevalent [4-6]. This clinical trial
evaluated the efficacy of CQ combined with SP in Central
Java, a setting where 47% of P. falciparum infections are
resistant to CQ and 22% resistant to SP [4]. Since single
dose primaquine is mandated on Java and Bali for trans-
mission blocking activity (only adds an additional $0.05
to the cost of therapy), a single dose of primaquine was
added to evaluate its impact on parasitological cure and
on post-treatment gametocytaemia.
Materials and methods
Study location
The study was conducted between July and October 2001
in Purworejo District in the Menoreh Hills near the south-
ern coast of Central Java, a region experiencing resurgent
malaria at that time. The social, economic and demo-
graphic characteristics of malaria in the region are
described elsewhere [4,7,8]. Falciparum and vivax malaria
(approximately 1:1) occurs among all ages with preva-
lence in high-risk areas ranging from 5% to 38%. Among
40 and 54 subjects treated with CQ or SP for uncompli-
cated falciparum malaria in this region, 47% and 22%,
respectively, developed recurrent parasitaemia within 28
days [4]. During the close study follow up, none of the
treatment failures developed complicated or severe
malaria.
Study subjects, screening and enrollment
Subject enrollment is depicted in Figure 1. Subjects with
uncomplicated falciparum malaria were recruited, in part,
by mass blood survey and by passive case detection (PCD)
at local government-run clinics. This was necessary
because few adults in this study area suffered from symp-
tomatic malaria. After informed consent, all subjects were
screened by medical history, physical examination, semi-
quantitative glucose-6-phosphate dehydrogenase (G6PD)
assay (G-6-PDH Screening Test 203-A, Sigma Diagnos-
tics®, St. Louis, MO USA), and if female of child-bearing
potential, a urine human chorionic gonadotropin (hCG)
test (TestPack® +Plus™ hCG Urine, Abbott, USA). Inclu-
sion criteria included age ≥ 15, asexual stage P. falciparum
parasite density ≥ 400/μl on Giemsa thick smear exam-
ined by standard microscopy, and availability for 28-day
follow-up. Exclusion criteria included pregnancy, breast
feeding, body weight < 40 kg, G6PD deficiency, history of
antimalarial or antibiotic consumption during the previ-
ous 7 days, severe or complicated malaria, history of
allergy or adverse reaction to study medications, and P.
vivax or mixed species infection. Any parasitemic potential
study subject not meeting these criteria was referred back
to the cooperating clinic for standard therapy. Those
patients deemed to meet enrollment criteria and willing
to participate were assigned a sequential study subject
code by the screening physician. The study subject codes
were pre-assigned to treatment arms by a random process
and all treatment was pre-packaged accordingly.
Treatment and follow-up
Subjects were randomized to one of four treatment arms:
(A) CQ 25 mg base/kg (body weight) over three days, (B)
CQ 25 mg/kg over three days + SP 25/1.25 mg/kg single
dose, (C) CQ 25 mg/kg over three days + SP 25/1.25 mg/
kg single dose + primaquine 45 mg single dose on day 0,
or (D) CQ 25 mg/kg over three days + SP 25/1.25 mg/kg
single dose + primaquine 45 mg single dose on day 2.
Study investigators directly observed and documented
administration of each dose of medication: CQ (Res-
ochin®; chloroquine diphosphate tablets 150 mg base; PT
Bayer, Indonesia) in three once daily doses of 10, 10 and
5 mg base/kg on days 0,1, and 2 respectively; SP (Fan-
sidar® tablets; 500 mg sulfadoxine/25 mg pyrimethamine;Malaria Journal 2006, 5:108 http://www.malariajournal.com/content/5/1/108
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Hoffman La Roche, Indonesia) in a single dose on day 0;
Primaquine phosphate (generic tablets, 15 mg base; PT
Kimia Farma, Bandung, Indonesia) in a single dose of 3
tablets on day 0 or day 2.
Subjects were followed for 28 days after initiating therapy.
Study personnel visited subjects on 10 separate days (1, 2,
3, 4, 7, 11, 14, 18, 21 and 28) to assess symptoms, clinical
recovery, adverse events and to obtain finger-stick blood
samples for preparation of Giemsa-stained blood smears.
Subjects complaining of illness on any day of follow-up
were immediately brought to clinic and evaluated. Blood
blot specimens (100 – 200 μl) were also prepared on days
0, 2, 7, 14, 21, 28 or day of recurrent parasitaemia from
fingerstick blood samples collected by heparinized, 100 μl
micro-capillary tubes and expelled onto Whatman No. 1
filter paper (Whatman International, United Kingdom)
for drying and storage for later analysis.
Microscopy
The microscopists in this study were certified as compe-
tent by a standardized, proctored examination. Micro-
scopists examined all ocular fields of standard Giemsa
(Sigma, USA) stained thick smears at high power (1000×
oil immersion) for asexual and sexual forms of P. falci-
parum and other plasmodial species, and recorded sexual
and asexual parasite densities as number of parasites per
200 white blood cells. Parasite densities are reported as
parasites/μL assuming an average white blood cell count
of 8,000/μl.
Table 1: Comparison of clinical trials to evaluate the efficacy of chloroquine (CQ) + sulfadoxine/pyrimethamine (SP)
Study Location Year N CQ Efficacy SP Efficacy CQ + SP Efficacy Endpoint in 
Days
Comparison of 
CQ+SP vs. CQ, 
CQ+SP vs. SP
Reference
Nigeria 2004 153 n/a n/a 90% 28 n/a [30]
Laos 2003 110 n/a n/a 93% 42 n/a
n/a
[14]
Bangladesh 2002 133 n/a n/a 72% 28 n/a [18]
Eastern Uganda 2002 280 n/a 42% 60% 28 n/a
p = ns
[21]
Southern Uganda 2002 448 n/a 70% 83% 14 n/a
p < 0.001
[12]
Western Uganda 2001 141 93% 100% 100% 14 p = ns
p = ns
[13]
Southern Laos 2001 119 55% 82% 83% 14 p = 0.029
p = ns
[19]
Papua, Indonesia 1999 169 17% 79% 62% 28 p < 0.001
p = 0.047
[17]
Southwest Nigeria 1999 111 93% n/a 96% 28 n/a
p = ns
[22]
Papua New Guinea 1998–1999 513* n/a n/a 95% 28 n/a [3]
The Gambia 1995 405 n/a 90% 95% 28 n/a
p = ns
[20]
Mumbai, India N/a 49 36% n/a 87% 42 p < 0.026
n/a
[2]
ns = not significant
n/a = not available
* children were treated with amodiaquine + SP (303 of the 513), ** excluding childrenMalaria Journal 2006, 5:108 http://www.malariajournal.com/content/5/1/108
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Merozoite Surface Protein-2 (msp-2) genotyping
Msp-2 genotyping was performed on blood blot samples
from day 0 and day of recurrent P. falciparum parasitaemia
following Felger et al. [9]. Recrudescence was defined by
the presence of the same genotype on day 0 and day of
recurrent parasitaemia while a new infection (i.e. reinfec-
tion) was defined by the presence of a different genotype
on day 0 and day of recurrent parasitaemia.
Determination of therapeutic outcomes and data analysis
Therapeutic efficacy (parasitological cure) was defined as
the proportion of subjects reaching day-28 without recru-
descence. Therapeutic failures occurred when asexual par-
asitaemia increased between day 0 and day 2, failed to
clear by day 4, or recurred between days 4 and 28. These
data were used to determine the crude therapeutic efficacy
of each regimen. Infections initially classified as therapeu-
tic failures but later proven to be reinfections by msp-2
genotyping were reclassified as therapeutic successes with
abbreviated follow-up (until the point of censure). These
results were used to determine the "adjusted" efficacies of
CQ and CQ + SP. EpiInfo 2000 1.1.2 (CDC, Atlanta USA)
and SPSS version 9.0 (SPSS, Inc. USA) were used to calcu-
late confidence intervals for odds ratios (OR) and the 95%
confidence interval around those ratios, and for estimat-
ing the p-value using the Yates' corrected or Fisher's exact
The recruitment, enrollment and randomization process for this study evaluating four treatment regimens for uncomplicated P.  falciparum in residents of Purworejo District, Central Java, Indonesia Figure 1
The recruitment, enrollment and randomization process for this study evaluating four treatment regimens for uncomplicated P. 
falciparum in residents of Purworejo District, Central Java, Indonesia.
124 patients with P.
falciparum identified 
       SCREENING
1. Mass blood survey
 2. Clinic referral 
7 ineligible by 
inclusion / 
exclusion criteria 
117 eligible for 
enrollment and 
willing to volunteer 
Treatment as per 
national guidelines 
RANDOMIZED TO: 
1. CQ         (n=29) 
2. CQ+SP       (n=32) 
3. CQ+SP+PQ (day 0)   (n=28) 
4. CQ+SP+PQ (day 2)   (n=28) Malaria Journal 2006, 5:108 http://www.malariajournal.com/content/5/1/108
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test when appropriate. Cumulative incidence of therapeu-
tic failure was estimated by actuarial analysis as described
elsewhere [10].
Results
Enrollment
Among 124 parasitaemic persons identified during mass
blood screening and passive case detection from outpa-
tient clinics, 117 were enrolled and randomized to one of
the 4 treatment regimens. Seven subjects did not meet
study eligibility criteria and were returned to the referring
clinic for treatment for the following reasons: taking qui-
nine (1), pregnancy (1), G6PD deficiency (1), low body
weight (2), declined participation (1) and administrative
error (1).
Demographics
Among the 117 subjects enrolled and randomly assigned,
no statistically significant demographic differences
between the four study arms were identified; age ranged
from 16 to 65 years, and the male to female ratio was
1.2:1 (Table 2). No statistically significant differences
were noted between treatment arms with regards to fever
rates (range 24–41%) or geometric mean asexual parasite
densities (range 653-1465/μL) before enrollment.
Parasite and fever clearance times
There were no significant differences in parasite or fever
clearance times among the 4 treatment groups. Virtually
all (115 of 117) subjects cleared parasitaemia by day 3
regardless of the therapy assignment, and all 38 subjects
with fever prior to therapy had a normal axillary tempera-
ture by day 2 (Figure 2).
Crude therapeutic efficacy of CQ vs. CQ + SP
Asexual parasitemia outcomes were similarly efficacious
among the three groups receiving (CQ+SP, CQ+SP+PQ0,
and CQ+SP+PQ2), so these groups were combined specif-
ically for comparison with CQ monotherapy against asex-
ual blood stages.
Among the 29 subjects treated with CQ alone, 1 (3%)
withdrew from the study after day 18 and 3 (10%) devel-
oped intercurrent P. vivax during the second and third
week of post-therapy observation. Fourteen (48%) com-
pleted the study without recurrent parasitaemia. The
remaining 11 (38%) subjects developed recurrent P. falci-
parum during the 28-day follow-up. The crude cumulative
incidence of failure of CQ therapy for uncomplicated P.
falciparum was 42% (Table 3); therefore, the crude thera-
peutic efficacy was 58%.
Among the 88 subjects treated with CQ + SP, six (7%)
withdrew before day 28 (three declined further participa-
tion between days two and 21 and three moved away
from the study site between days one and 18). One subject
(1%) developed intercurrent P. vivax (day 22). Seventy-six
(86%) completed the study without recurrent parasitae-
mia. The remaining 5 (6%) subjects developed recurrent
P. falciparum during follow-up, therefore providing a
crude therapeutic efficacy of 94%. The crude 28-day
cumulative incidence of failure of CQ + SP therapy was
6% (Table 3). The relative risk of treatment failure with
CQ compared to CQ + SP among those who completed
the 28-day observation period was 7.13 (95% CI 2.74 –
18.57, p = 0.00003).
Adjusted efficacy of CQ vs. CQ + SP
Three of 11 apparent therapeutic failures among subjects
receiving CQ alone could not be evaluated because P. fal-
ciparum DNA could not be amplified for msp-2 genotyp-
ing, leaving eight evaluable recurrent infections. One case
of day 28 recurrent parasitaemia was reclassified as a cure
with late reinfection based on differing day 0 and day of
recurrence msp-2  genotypes. From the remaining seven
recurrent infections, the parasite genotypes matched and
their classification as recrudescence affirmed. The
adjusted cumulative incidence of failure of CQ therapy for
uncomplicated P. falciparum was therefore 30% (thera-
peutic efficacy 70%) (Table 4).
In the combined CQ + SP groups, one of five recurrent
parasitaemias was excluded from analysis because para-
site DNA could not be amplified, leaving four evaluable
recurrent infections. Based on discordant day 0 and day of
recurrence  msp-2  genotypes, three apparent therapeutic
failures were reclassified as successful cures with reinfec-
tion. The 28-day cumulative incidence of failure of
CQ+SP therapy for uncomplicated P. falciparum was there-
fore only 1% (therapeutic efficacy = 99%) (Table 4). Sub-
jects treated with CQ alone were 25 times more likely to
suffer therapeutic failure compared to CQ combined with
SP (95% CI 3.3 – 196.06; p = 0.0006).
Effect of primaquine on gametocytaemia
Figure 3 illustrates the course of gametocyte rates among
groups after treatment. Comparing the two groups receiv-
ing primaquine, gametocyte rates declined steadily to 0%
by day 11 after therapy and did not reappear during fol-
low-up. Gametocyte rates declined more slowly in the
non-primaquine groups. The difference in gametocyte
clearance rates on day 11 between groups receiving pri-
maquine (0%) and those not (33%) was significant (p =
0.025). A single dose of primaquine greatly improved the
clearance rate of gametocytes, and administering the dose
on day 2 vice day 0 accelerated clearance time (0% vs. 7%
on day 7); however this difference was not statistically sig-
nificant.Malaria Journal 2006, 5:108 http://www.malariajournal.com/content/5/1/108
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Conclusion
The combination of CQ+SP proved 99% effective among
87 subjects with uncomplicated falciparum malaria in
Central Java, Indonesia. Similarly excellent efficacy has
been reported from other regions [2,11-14], including
Papua New Guinea[3]. However, in eastern Indonesia,
where resistance to CQ (up to 95%)[5] and SP (range 15–
54%) [15,16] is much more prevalent than in Central
Java, the combination of CQ + SP fails in 38%[17] to 55%
(Maguire, personal communication) of subjects with
uncomplicated falciparum malaria. Poor efficacy of
CQ+SP has been reported elsewhere as well [18] and stud-
ies in The Gambia, Uganda, Laos and Nigeria, for exam-
ple, showed similarly poor efficacy or negligible
difference with combining CQ and SP [13,19-22]. The
apparent wide range of efficacy of CQ+SP requires infor-
mation-based decisions about its use as a therapeutic
option in any given area.
Table 2: Demographic, clinical and parasitological characteristics of subjects treated with 4 malaria regimens in Purworejo District, 
Indonesia
Treatment group Summary statistic
CQ alone CQ + SP CQ + SP + PQ0 CQ + SP + PQ2
Sample size 29 32 28 28 n/a
Male: Female 1.2 : 1 1.5 : 1 1 : 1.2 1.3 : 1 p = 0.771a
Mean age (range) 36 (17–55) 40 (20–60) 40 (20–62) 35 (16–65) p = 0.256b
Geometric mean asexual parasite 
density (95% CI)
653 (382–1118) 1465 (849–2531) 1148 (582–2263) 1409 (720–2760) p = 0.286b
Fever Rate 24% 41% 29% 36% p = 0.529a
CQ = chloroquine, SP = sulfadoxine/pyrimethamine, PQ0 = primaquine on day 0, PQ2 = primaquine on day 2, 95% CI = 95% confidence interval
n/a – not applicable
a) Chi-square test
b) Kruskal-Wallis test
(A) Asexual parasite clearance time in 117 subjects with falciparum malaria after treatment with one of 4 different regimens.  (B) Time of fever clearance in 38 subjects with fever at the time of study enrollment Figure 2
(A) Asexual parasite clearance time in 117 subjects with falciparum malaria after treatment with one of 4 different regimens. 
(B) Time of fever clearance in 38 subjects with fever at the time of study enrollment. CQ = chloroquine, SP = sulfadoxine/
pyrimethamine, and PQ = primaquine on either day 0 (d0) or day 2(d2) of therapy.Malaria Journal 2006, 5:108 http://www.malariajournal.com/content/5/1/108
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Despite the marked differences between day-28 cure rates,
CQ vs. CQ+SP regimens had essentially identical parasite
and fever clearance times. These two indices parallel clin-
ical recovery and almost certainly exacerbate the persistent
over-the-counter marketing and unsupervised use of CQ
monotherapy. Indeed, surveys of knowledge, attitudes
and practices in the region of study[23] affirmed this prac-
tice as common. Moreover, CQ remains first-line therapy
against vivax malaria, even though accurate diagnostic
services to distinguish these species are available to rela-
tively few people. For all of these reasons, CQ remains a
widely used drug against P. falciparum and other species of
malaria in Indonesia.
CQ+SP can not be suggested as a first-line treatment pol-
icy that would be supported by comprehensive national
programs of patient awareness, health provider training,
and widespread distribution and marketing. The efficacy
Table 3: Life Table representation of cumulative incidence of crude therapeutic failure attributable to drug resistance among subjects 
treated with chloroquine (CQ) and CQ + sulfadoxine/pyrimethamine (SP) without distinguishing recrudescence from reinfection
CQ CQ+SP
D N I W IR CIF D N I W IR CIF
0 29 0 0 0.00 0.00 0 88 0 0 0.00 0.00
2 29 0 0 0.00 0.00 2 88 0 2 0.00 0.00
4 29 0 0 0.00 0.00 4 86 1 1 0.01 0.01
7 29 0 0 0.00 0.00 7 84 1 0 0.01 0.02
11 29 1 0 0.03 0.03 11 83 0 0 0.00 0.02
14 28 2 1 0.07 0.10 14 83 0 0 0.00 0.02
18 25 2 1 0.08 0.18 18 83 0 2 0.00 0.02
21 22 2 2 0.10 0.26 21 81 0 1 0.00 0.02
28 18 4 0 0.22 0.42 28 80 3 1 0.04 0.06
N = sample at risk of therapeutic failure at start of interval
i = the number of cases of therapeutic failure during the interval
w = the number of subjects withdrawn from the test during the interval due to exclusion from analysis, loss to follow-up after latest blood smear, 
intercurrent infection with another plasmodia species, or reinfection by different genotype P. falciparum or relapse/reinfection by P. vivax based on 
day of recurrent parasitemia CQ +DCQ concentrations
IR = risk of therapeutic failure in the interval, calculated as i/(N-w/2)
CIF = cumulative incidence of therapeutic failure, calculated as 1-[(1-IRn)(1-CIFn-1)], where IRn is the IR in the current interval and CIFn-1 is the 
cumulative incidence up to the previous interval
Table 4: Life Table representation of cumulative incidence of adjusted therapeutic failure attributable to drug resistance among 
subjects treated with chloroquine (CQ) and CQ + sulfadoxine/pyrimethamine (SP) with msp-2 genotyping to distinguish recrudescence 
from reinfection
CQ CQ+SP
D N I W IR CIF D N I W IR CIF
0 26 0 0 0.00 0.00 0 87 0 0 0.00 0.00
2 26 0 0 0.00 0.00 2 87 0 2 0.00 0.00
4 26 0 0 0.00 0.00 4 85 1 1 0.01 0.01
7 26 0 0 0.00 0.00 7 83 0 0 0.00 0.01
11 26 1 0 0.04 0.04 11 83 0 0 0.00 0.01
14 25 1 1 0.04 0.08 14 83 0 0 0.00 0.01
18 23 1 1 0.04 0.12 18 83 0 2 0.00 0.01
21 21 1 2 0.05 0.16 21 81 0 1 0.00 0.01
28 18 3 0 0.17 0.30 28 80 0 2 0.00 0.01
N = sample at risk of therapeutic failure at start of interval
i = the number of cases of therapeutic failure during the interval
w = the number of subjects withdrawn from the test during the interval due to exclusion from analysis, loss to follow-up after latest blood smear, 
intercurrent infection with another plasmodia species, or reinfection by different genotype P. falciparum or relapse/reinfection by P. vivax based on 
day of recurrent parasitemia CQ +DCQ concentrations
IR = risk of therapeutic failure in the interval, calculated as i/(N-w/2)
CIF = cumulative incidence of therapeutic failure, calculated as 1-[(1-IRn)(1-CIFn-1)], where IRn is the IR in the current interval and CIFn-1 is the 
cumulative incidence up to the previous intervalMalaria Journal 2006, 5:108 http://www.malariajournal.com/content/5/1/108
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of the combination may not be sufficiently long-lived to
support these costly adjustments and measures. However,
CQ combined with SP may be a feasible therapeutic
option in regions with evidence of treatment efficacy
where health care providers are unable to use ACT because
of problems with availability, fear of side effects or coun-
terfeit drug. Use should be limited to areas like Central
Java, where data suggests that CQ+SP efficacy was better
than 95%.
Primaquine has proven gametocytocidal activity against
P. falciparum. A single 45 mg dose reduces gametocyte
clearance time to 2 to 3 days [24], nearly one week faster
than with other asexual stage antimalarials alone [25].
The addition of primaquine to standard blood schizonti-
cidal therapy significantly reduced the point prevalence of
malaria in one study [26]. Various primaquine regimens
appear equally efficacious[27]; however, its use may be
limited by the frequency of G-6-PD deficiency and spo-
radic supplies[28,29]. In our study, addition of a single 45
mg dose of primaquine on either day 0 or day 2 signifi-
cantly offset the persistence of gametocytaemia. Current
P. falciparum malaria treatment policy in Indonesia
includes administration of 45 mg of primaquine on day 0
of treatment in hypoendemic areas. This study supports
its continued use in Indonesia, especially with combina-
tion regimens containing SP, which has been linked to
sulfonamide-associated gametocyte proliferation [17].
Combining artesunate with SP similarly reduced gameto-
cyte rates below that observed with SP alone in one study
in Indonesia[15]; similarly, artesunate combined with
amodiaquine significantly reduced gametocyte carriage in
comparison to CQ+SP in Nigerian children[30].
In summary CQ+SP combination was highly effective for
parasitological cure in subjects with uncomplicated P. fal-
ciparum in Central Java, Indonesia. The regimen was safe
and efficacious, and it is inexpensive and readily available
throughout Indonesia. A single dose of 45 mg pri-
maquine, either on day 0 or day 2, suppressed or quickly
eliminated gametocytaemia. Given wide regional differ-
ences in efficacy of CQ+SP, this regimen should be evalu-
ated where its use is advocated as a therapeutic option for
falciparum malaria.
Gametocyte rates in 117 subjects with falciparum malaria after treatment with one of 4 different regimens Figure 3
Gametocyte rates in 117 subjects with falciparum malaria after treatment with one of 4 different regimens. CQ = chloroquine, 
SP = sulfadoxine/pyrimethamine, and PQ = primaquine on either day 0 (d0) or day 2(d2) of therapy.
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